Want to join the conversation?
$CELG's sales from multiple myeloma drug Revlimid for 2015 increased by 16.5% from last year. This was primarily due to increased unit sales in both U.S. and international markets in addition to price rises in the U.S. market. Increases in market penetration and treatment duration of patients contributed to the increase in U.S. unit sales.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.